Skip to main content

Parkinson's Disease clinical trials at UCSF
13 in progress, 6 open to new patients

  • Chronic Effects of DBS in Parkinson's Disease and Dystonia

    open to eligible people ages 22–75

    The purpose of this study is to use an investigational device to record brain activity for 12-24 months following surgical implantation of deep brain stimulation (DBS) systems. The goal of the study is better understanding of brain activity in movement disorders and how they relate to DBS, not to bring new devices to market.

    San Francisco, California

  • More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

    open to eligible people ages 18–105

    This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple systems atrophy (MSA), Lewy Body Dementia (LBD). It will utilize a randomized stepped-wedge design to compare patient and caregiver outcomes between usual care in the community versus usual care augmented by palliative training and telemedicine support to provide other resources (e.g. social work).

    San Francisco, California and other locations

  • Safety and Biomarker Study of EPI-589 in Parkinson's Disease

    open to eligible people ages 21–75

    Open-label study with 30-day run-in phase and adaptive design component to include more subjects if deemed appropriate by investigators.

    San Francisco, California and other locations

  • Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

    open to eligible people ages 40–75

    Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

    San Francisco, California and other locations

  • Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

    open to eligible people ages 30 years and up

    This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.

    Sunnyvale, California and other locations

  • Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes

    open to eligible people ages 21 years and up

    The purpose of this study is to determine the safety and effectiveness of a new procedure for placing DBS electrodes, in which the entire surgery is performed within an MRI scanner ("interventional MRI"), with the patient fully asleep (under general anesthesia). The standard method for the placement of deep brain stimulators does not use MRI during the actual DBS placement. The standard method involves placement of a rigid frame on the patient's head, performance of a short MRI scan, transport to the operating room, placement of the DBS electrodes in the operating room, and return to the MRI suite for another MR to confirm correct electrode placement. In the standard method, the patient must be awake for 2-4 hours in the operating room to have "brain mapping" performed, where the brain target is confirmed by passing "microelectrodes" (thin wires) into the brain to record its electrical activity. In the standard method, general anesthesia is not required. In this study, the surgery is guided entirely by MRI images performed multiple times as the DBS electrode is advanced. This eliminates the need for the patient to be awake, and eliminates the need for passing microelectrodes into the brain before placing the permanent DBS electrode.

    San Francisco, California

  • A Study to Evaluate the Efficacy of RO7046015 in Participants With Early Parkinson's Disease

    Sorry, not currently recruiting here

    This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous RO7046015 versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2).

    San Francisco, California and other locations

  • Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients

    Sorry, accepting new patients by invitation only

    This study will investigate cortical stimulation to treat mood and behavioral symptoms in Parkinson's disease patients.

    San Francisco, California

  • Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?

    Sorry, in progress, not accepting new patients

    The purpose of this study is to improve outcomes for persons living with Parkinson's Disease (PD) and their family caregivers. The investigators hypothesize that outpatient interdisciplinary palliative care will improve patient-centered outcomes for PD patients at high-risk for poor outcomes.

    San Francisco, California and other locations

  • Efficacy of Isradipine in Early Parkinson Disease

    Sorry, in progress, not accepting new patients

    The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.

    San Francisco, California and other locations

  • Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease. CERE-120 is an experimental drug that consists of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. Similar to other growth factors (such as GDNF), neurturin is capable of restoring function and protecting brain cells from further damage. The virus used in CERE-120 is not known to cause disease in people. CERE-120 is delivered directly to the brain cells most affected in Parkinson's disease - the dopamine producing neurons. CERE-120 is injected during brain surgery. Once in place, CERE-120 continuously produces neurturin.

    San Francisco, California and other locations

  • Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Safety study of AADC gene transfer (VY-AADC01) in subjects with Parkinson's disease.

    San Francisco, California and other locations

  • Study of Urate Elevation in Parkinson's Disease, Phase 3

    Sorry, in progress, not accepting new patients

    A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD. Clinical decline will be assessed as change in the primary outcome variable of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a composite scale comprising patient- and clinician-reported outcomes.

    San Francisco, California and other locations